<Anchor>

Among these, an American pharmaceutical company revealed that antibodies were made in all participants in clinical trials of the Corona19 vaccine. We still have to go through more clinical trials, but today's (19th) US stocks rose sharply as expectations for vaccine development grew.

First, reporter Kim Jeong-ki.

<Reporter>

US pharmaceutical company Moderna announced the results of a phase 1 clinical trial for a candidate for Corona19 vaccine.

Corona19 antibody was formed in all 45 people who received the candidate.

Participants were divided into three groups and administered 2 times at 25, 100, and 250 µg intervals at 4 weeks intervals. In the group with the lowest dose of 25 µg, an antibody similar to that of the infected person was formed, and 100 µg was administered. One group explained that antibodies were produced that surpassed those who had been infected and recovered.

Eight test participants also reported that they had made neutralizing antibodies that neutralized the virus.

[Jacks / Moderna Senior Researcher: This is a very important first step in a long journey to develop vaccines.]

Modena will soon enter a phase 2 trial with 600 people and will begin a phase 3 trial with thousands in July. He said he would.

If this process went smoothly, I was confident that vaccines could be produced later this year or early next year.

The New York stock market closed at 3.85% in anticipation of a corona vaccine, the biggest gain since April.

As competition for vaccine development is fierce worldwide, there are currently 8 vaccine candidates tested in humans.

(Video editing: Jeon Min-kyu)